# Accepted Manuscript

Rapid diagnostic tests for determining dengue serostatus: a systematic review and key informant interviews

Robert Luo, Noah Fongwen, Cassandra Kelly-Cirino, Eva Harris, Annelies Wilder-Smith, Rosanna Peeling

Please cite this article as: Luo R, Fongwen N, Kelly-Cirino C, Harris E, Wilder-Smith A, Peeling R, Rapid diagnostic tests for determining dengue serostatus: a systematic review and key informant interviews, *Clinical Microbiology and Infection*, https://doi.org/10.1016/j.cmi.2019.01.002.

1   Rapid diagnostic tests for determining dengue serostatus:

2   a systematic review and key informant interviews

3

4   Robert Luo[1*], Noah Fongwen[1], Cassandra Kelly-Cirino[2], Eva Harris[3],

5   Annelies Wilder-Smith[4,5], Rosanna Peeling[1]

6

7 [1] International Diagnostics Centre, London School of Hygiene and Tropical Medicine, London, UK

8 [2] Foundation for Innovative New Diagnostics, Geneva, Switzerland

9 [3] Division of Infectious Diseases and Vaccinology, School of Public Health, University of

10 California, Berkeley, USA

11 [4] World Health Organization, Geneva, Switzerland

12 [5] Department for Disease Control, London School of Hygiene and Tropical Medicine, London, UK

13

14 Intended Category: Systematic Review

15

16 * Corresponding Author:

17 E-mail: rluodx@gmail.com

Abstract

Objectives: Vaccination for dengue with the live attenuated tetravalent CYD-TDV vaccine (Dengvaxia®) is only recommended in individuals who have had prior dengue virus (DENV) infection. Rapid diagnostic tests (RDT) for past DENV infection would offer a convenient method for pre-vaccination screening at point-of-care. A systematic review was conducted to evaluate the performance of current dengue rapid diagnostic tests (RDTs) for determining dengue serostatus, using IgG antibodies against DENV as a marker of past infection.

Methods: PubMed and EMBASE databases were searched from 2000 to 2018 to identify studies evaluating dengue RDTs in individuals with known or possible previous DENV infection. Study quality was evaluated using GRADE and QUADAS-2 criteria. Semi-structured interviews were also performed with available dengue RDT manufacturers.

Results: The performance of 4 dengue IgG RDTs was determined in 3137 individuals across 10 studies conducted in 13 countries, with serum used in most of the studies. No studies reported data for determining dengue serostatus, and limited data were available regarding cross-reactivity with other viruses. The majority of studies demonstrated sensitivities and specificities between 80-100% for dengue IgG detection in samples from secondary infection or convalescent timepoints after recent infection.

Conclusions: Although current dengue IgG RDTs have shown reasonable performance compared to laboratory-based tests in secondary infection, additional research is needed to determine how RDTs would perform in relevant populations targeted for vaccination. New RDTs or modifications to current RDTs are feasible and may optimize the performance of these tests for use in a pre-vaccination screening approach.

Introduction

Dengue is a flavivirus infection spread by *Aedes aegypti* and *Aedes albopictus* mosquitoes and is estimated to infect up to 400 million people worldwide each year [1]. Four distinct dengue virus serotypes (DENV-1 through DENV-4) cause dengue. After infection with one serotype, an individual develops lifelong immunity to that serotype, but subsequent infection with another serotype increases the risk of severe dengue due to antibody dependent enhancement of infection [2]. The annual incidence of DENV infections has increased exponentially over the past decades, accompanied by continual geographic expansion to new areas [3,4]. International travelers are also increasingly affected [5-8]. Effective vector control strategies are not sustainable [3], community-based approaches have had mixed results [9,10], and compliance with personal protective measures is difficult [11]. Hence, a dengue vaccine would be an important tool to combat the dengue burden.

Currently, the only commercially available dengue vaccine is a tetravalent live attenuated recombinant vaccine, CYD-TDV (Dengvaxia®), that was developed by Sanofi-Pasteur. Licensed in approximately 20 countries (as of July 2018) for use in individuals between 9 and 45 years of age in most countries, it is given with a 3-dose schedule six months apart [12]. In late 2017, Sanofi-Pasteur released long-term safety data stratified by serostatus [13]. Serostatus refers to whether a person has had a previous DENV infection prior to vaccination: a seropositive person has had at least one past DENV infection, whereas a seronegative person is dengue-naïve [14]. Follow-up data of trial participants who were seronegative prior to administration of the vaccine

61   showed a 1.75-fold increased risk of hospitalizations due to dengue and severe dengue from

62   year 3 onwards in comparison with unvaccinated seronegative participants. This unanticipated

63   outcome is thought to be mediated by antibody dependent enhancement of infection, where

64   non-neutralizing antibodies can facilitate greater viral entry into monocytes through Fc receptor

65   binding. This can lead to higher viral load, greater immune activation, and increased risk for

66   severe dengue. In seropositive individuals, the vaccine was efficacious and safe, conferring long-

67   term protection [13]. Consequently, in April 2018, WHO`s Strategic Advisory Group of Experts on

68   Immunization (SAGE) revised its recommendations to state a "pre-vaccination screening

69   strategy" would be the preferred option for countries seeking to use Dengvaxia®, a strategy

70   whereby only dengue-seropositive individuals should be vaccinated [15-17].

71

72   The choice of tests for dengue diagnosis depends on the timing and purpose. For the diagnosis

73   of acute DENV infection, tests are based on DENV isolation, presence of dengue viral antigens,

74   detection of viral nucleic acid in blood through techniques such as RT-PCR, IgM seroconversion,

75   and/or a four-fold or greater rise in IgG antibody titer in paired blood samples collected at least

76   14 days apart [18]. Dengue virus and antigen detection are the most accurate diagnostic tools

77   during the first 5 days of illness, as IgG and IgM antibodies are not produced until 5-7 days after

78   the onset of symptoms in primary infections [19,20]. IgM levels can become undetectable after

79   3-6 months, while IgG levels often persist over an individual's lifetime and can be used to

80   indicate previous DENV infection [19]. Thus, for the detection of past DENV infections, IgG

81   antibodies to DENV serve as a marker of past DENV infection. Enzyme-linked immunosorbent

82 assays (ELISAs) are the most commonly used laboratory-based serology assays to measure DENV

83 IgG. However, ELISAs are time-consuming and require significant laboratory infrastructure,

84 including instrumentation, trained staff, and refrigeration for reagents. Delays in turnaround

85 time would hamper vaccination campaigns as patients would likely be lost to follow-up if

86 required to return several days later for vaccination. The plaque reduction neutralization test

87 (PRNT), which measures the titer of neutralizing antibodies against DENV infection, has also

88 been used to evaluate dengue serostatus, but is even more laborious and expensive than ELISAs,

89 and hence not routinely used [20]. All serological assays can exhibit some degree of cross-

90 reactivity with other flaviviruses such as Zika, Japanese encephalitis and yellow fever [21].

91 Rapid diagnostic tests could enable quick, simple screening in dengue endemic areas, which are

92 often resource-limited and do not have the laboratory capacity to perform ELISA or PRNT

93 testing. RDTs would also provide with results at the point-of-care to ensure safe vaccine

94 administration. However, the disadvantage of currently available RDTs is that they have not yet

95 been validated for screening for past DENV infection and may lack sufficient sensitivity and

96 specificity to ensure effective vaccination strategies. Since RDTs have typically only been

97 evaluated in the context of acute DENV infection and not for the detection of past infection, a

98 systematic review was performed to evaluate the sensitivity and specificity of commercially

99 available RDTs used for detecting IgG antibodies against DENV as a marker of previous DENV

100 infection.

101 **Methods**

102   A systematic review was performed according to the Preferring Reporting Items for Systematic

103   Reviews and Meta-Analyses (PRISMA) [22]. PubMed and EMBASE databases were searched

104   from January 1, 2000, to May 31, 2018 to identify relevant publications in peer-reviewed

105   journals as original scientific research. Search terms were based on a PICO (population,

106   intervention, comparator, and outcome) question format. The population encompassed

107   individuals with known or possible previous DENV infection. The intervention was use of RDTs

108   for detection of DENV IgG antibodies, with the comparator being a validated laboratory-based

109   ELISA or PRNT assay. The primary outcome was previous DENV infection, which was measured

110   in studies by the sensitivity and specificity for IgG detection. The search was performed using

111   the following terms: (dengue OR "dengue virus" OR "dengue fever") AND ("rapid diagnostic

112   test" OR "rapid test") AND (IgG OR sensitivity OR specificity OR "commercially available" OR

113   "prior infection" OR "previous infection" OR "convalescent" OR seropositive OR seropositivity).

114

115

116   After all studies were retrieved, two reviewers independently reviewed all potentially relevant

117   studies in full. Disagreements between reviewers were resolved with further discussion

118   between the two primary reviewers. Studies were included if they met the following inclusion

119   criteria: studies evaluating the performance of RDTs that are able to test for DENV IgG, studies

120   comparing RDTs to an established laboratory-based reference standard for determining DENV

121   infection status, and studies involving samples from patients with prior DENV infection. Studies

122   were excluded if they contained one or more of the following exclusion criteria: studies on the

123   use of RDTs for diagnosing acute primary infection only, studies on non-commercially available

6

124   assays, studies not including an RDT, studies using a reference standard that has not been

125   independently validated, or studies only having a clinical diagnosis as a reference standard.

126

127   Studies were summarized outlining the principal components of each cohort. The summary

128   included the authors, sample size, study location, test characteristics and reference standard.

129   Study results were extracted and summarized for all included studies. Impact on test

130   performance based on variables such as geographic location (if endemic for dengue and other

131   flaviviruses), travel history, previous vaccination status, DENV serotype, and previous infection

132   with other flaviviruses, were also considered. Data from all studies were aggregated, and

133   frequency statistics were run to describe the population tested across all studies. Forest plots

134   were generated to depict the range of sensitivity and specificity results for the RDTs studied.

135   The quality of each study was assessed following QUADAS-2 guidelines, and the complete body

136   of evidence was evaluated using GRADE guidelines [23,24].

137

138   Semi-structured telephone interviews were conducted by the primary author with dengue rapid

139   test product managers from all available dengue RDT manufacturers with commercially-

140   available tests that had published data. Questions were asked regarding the performance,

141   regulatory status, regional availability, intended use, and scientific principles regarding their

142   dengue RDT technology, the availability of data regarding serostatus determination with RDTs,

143   and the feasibility of updating the RDTs for use in determining dengue serostatus. Information

144   was evaluated qualitatively, and common answers regarding the current capabilities of dengue

145   RDTs and the potential for detection of dengue serostatus that were mentioned by a majority of

146   manufacturers were identified.

147

148   **Results**

149   The initial search identified 81 potential published studies for evaluation. Of these, 70 studies

150   did not meet the inclusion and exclusion criteria for the systematic review. Twenty-three studies

151   contained information on the sensitivity and specificity of dengue RDTs compared to

152   conventional laboratory-based ELISA testing. However, 13 of these studies were excluded since

153   they only evaluated RDT performance for acute primary DENV infection and did not provide

154   data on the performance of the IgG component for known or possible previous infection. After

155   filtering studies based on all inclusion and exclusion criteria, 10 studies were included in the

156   final systematic review (Fig 1).

157

158   **Fig 1. PRISMA Diagram**

159

160

161

162 The 10 studies included prospective and retrospective cohort studies [25-34]. Four dengue RDT

163 brands were represented: SD BIOLINE Dengue Duo (Alere/Abbott), Panbio Dengue Duo

164 (Alere/Abbott), OneStep Dengue Fever IgG/IgM RapiCard InstaTest (Cortez), and the GenBody

165 Dengue IgG/IgM test. Table 1 shows a summary of all studies, including information on the

166 types of samples tested and patient characteristics.

167 **Table 1. Study Summary**

Author, year, country	Test(s) Evaluated	Sample Size	Sample Type	Patient Characteristics	Reference Method	IgG Sensitivity (95% CI)	IgG Specificity (95% CI)
Vickers 2017 Jamaica	OneStep Dengue Fever IgG/IgM RapiCard InstaTest	339	Retrospective Serum	Suspected dengue; all ages	ELISA	All Samples: 44.4% (38.2-50.7%)	All Samples: 95.1% (88.0-98.7%)
Piedrahita 2016 Colombia	SD BIOLINE Dengue Duo	41	Prospective Serum	Suspected dengue; ages <18 years	ELISPOT-MNT	All Samples: 26.9% (7.9-41%)	All Samples: 66.7% (39.5-93.9%)
Vickers 2015 Jamaica	SD BIOLINE Dengue Duo	339	Retrospective Serum	Suspected dengue; Secondary infection:	ELISA	All Samples: 39.1% (33.3-45.2%) Secondary	All Samples: N/A Secondary

10

				IgM/IgG ratio <1.2; all ages		Infection: 52.1% (42-62%)	Infection: 100% (95.6-100%)
Krishnanant-hasivam 2015 Sri Lanka	SD BIOLINE Dengue Duo	143	Prospective Plasma	Suspected dengue	ELISA	All Samples: 38.8% (30.1-48.1%)	All Samples: 95.5% (77.1-99.2%)
Lee 2015 Malaysia	GenBody Dengue IgG/IgM, SD BIOLINE Dengue Duo, Panbio Dengue Duo	311	Prospective Whole Blood	Known dengue IgG positive and negative samples	ELISA	IgG-positive Samples Genbody: 96.7% SD BIOLINE: 82% Panbio: 75.3%	IgG-negative Samples Genbody: 100% SD BIOLINE: 100% Panbio: 100%
Pal	SD BIOLINE	834	Prospective	Suspected	IgG Capture	Convalescent	Convalescent

11

						Samples	Samples
2015 Peru, USA, Cambodia, Venezuela	Dengue Duo, Panbio Dengue Duo		and Retrospective Serum, Plasma, and Fingerstick Whole Blood	dengue; Convalescent timepoints: 15+ days after symptom onset; All ages	ELISA	SD BIOLINE: 93.9% (90.2-96.6%) Panbio: 98% (95.5-99.4%)	SD BIOLINE: 87.1% (84.1-89.8%) Panbio: 58.3% (54.2-62.4%)
Sanchez-Vargas 2014 Mexico	SD BIOLINE Dengue Duo	397	Prospective Serum	Secondary infection: IgG positive regardless of NS1 or IgM results; Negative samples from other febrile	IgG Capture ELISA	All Samples: 90.1% (85.3-94.8%) Secondary infection: 83.7% (72.3-95.0%)	All Samples: 92.5% (88.8-96.1%)

				illnesses			
Pan-Ngum 2013 Sri Lanka	Panbio Dengue Duo	549	Prospective Serum	Suspected dengue, ages ≥ 16 years	ELISA	All Samples: 61.9% (50.7-72.3%)	All Samples: 79.6% (75.6-83.1%)
Moorthy 2009 India	Panbio Dengue Duo	86	Retrospective Serum	Dengue-like illness	IgG Capture ELISA	All Samples: 87.5%	All Samples: 66.6%
Groen 2000 Curacao, Indonesia, Netherlands	Panbio Dengue Duo	132	Retrospective Serum	Suspected dengue; other viral infections	Consensus of multiple immunoas- says	All samples: 52%	All samples: 100%

168

169   Abbreviations: ELISA, enzyme-linked immunoassay. ELISPOT-MNT, enzyme-linked immunospot microneutralization test

170   In total, 3171 samples were tested with RDTs across all the studies. Sample types included

171   whole blood, plasma, and serum. No studies examined the performance of dengue RDTs to

172   detect remote previous infection. Eight of the 10 studies evaluated the ability of the IgG

173   component of the RDT to detect DENV IgG antibodies present in samples from all suspected or

174   known dengue patients being evaluated for DENV infection, compared to a laboratory-based IgG

175   ELISA test. Additionally, four of the 10 studies included samples from individuals described as

176   having secondary DENV infection (defined in studies as documented previous infection or IgG

177   positivity) or convalescent timepoints after recent infection (i.e., defined in one study as 15 days

178   or more after symptom onset), providing some insight into the performance of the IgG

179   component of the RDTs in individuals who had been infected with DENV previously.

180

181   Figure 2 shows the sensitivity of the dengue RDT IgG component from studies evaluating all

182   samples from patients with suspected or known DENV infection as well as studies with separate

183   categories for secondary DENV infection or convalescent timepoints after recent infection.

184

185   **Fig 2. Dengue RDT IgG Sensitivity Results**

186   Figure 2 shows the sensitivity estimates and 95% confidence intervals (when reported) for

187   detection of dengue IgG for each RDT evaluated. Sensitivity in samples from all suspected and

188   known dengue patients is shown in the top half of the figure, followed by sensitivity in samples

189   from secondary infections or convalescent timepoints after recent infection in the bottom half.

Dengue RDT IgG Component Sensitivity

190

191

192   The most commonly studied RDT was the SD BIOLINE Dengue Duo test, followed by the Panbio

193   Dengue Duo test, and all RDTs in this review could detect both IgG and IgM. When used in the

194   context of all samples being tested for DENV infection, the sensitivity of the RDT IgG component

195   typically ranged between 30-60%. However, when evaluated only in secondary infection or

196   convalescent timepoint samples, the sensitivity of the RDT IgG component was significantly

197   higher, typically between 75-98% with wide confidence intervals. This is consistent with the fact

198   that all samples under evaluation for DENV infection included cases of acute primary infection,

199   which would have had much lower levels or no IgG antibodies present, depending on when in

200   the course of infection the samples were drawn.

201

202   Figure 3 demonstrates the specificity of the dengue RDT IgG component reported across the

203   studies. In all samples under evaluation for DENV infection, the specificity of the dengue RDTs'

204   IgG component ranged from 65-100%, again with wide confidence intervals. When evaluated

205   only in cases of secondary infection or convalescent timepoints after recent infection, the

206   specificity rose to between 85-100% in most studies.

207

208   **Fig 3. Dengue RDT IgG Specificity Results**

209   Figure 3 shows the specificity estimates and 95% confidence intervals (when reported) for

210   detection of dengue IgG for each RDT evaluated. Specificity in samples from all suspected and

211   known dengue patients is shown in the top half of the figure, followed by specificity in samples

212   from secondary infections or convalescent timepoints after recent infection in the bottom half.

213

214

Dengue RDT IgG Component Specificity

215

216

Overall, there were no studies that directly evaluated the use of RDTs for determination of

dengue serostatus, as all studies examined RDT performance in the context of either all samples

from patients with possible DENV infection, and/or a subset from samples of secondary

infection or convalescent timepoints after recent DENV infection. Although all studies included

samples from dengue-endemic areas, none of them provided information on vaccination or

infection status of patients for other flaviviruses, all of which may lead to cross-reactivity with

dengue serological testing. Lack of cross-reactivity data is a major limitation for pre-vaccination

screening, since false-positive results due to cross-reactivity to other co-circulating flaviviruses

could lead to inappropriate vaccination of dengue-naïve individuals. Studies using samples that

have been well-characterized with either ELISA or PRNT for exposure to other flaviviruses,

particularly Zika virus given its genetic similarity to dengue, were absent. Additionally, the

228   majority of studies tested serum samples, and not whole blood samples, which are more

229   relevant for testing at the point-of-care. There were not enough studies using whole blood to

230   conclude whether or not the sensitivity and specificity of the test differed compared to serum or

231   plasma.

232

233   Table 2 summarizes the QUADAS-2 assessment by study, while Table 3 summarizes the GRADE

234   assessment of the complete body of evidence, using criteria from published guidelines [23,24].

235   In the QUADAS-2 assessment, there were high patient selection applicability concerns for all

236   studies, since none of the RDT tests were exclusively performed on patients with remote

237   previous DENV infection. This also lead to unclear applicability of the index test, since the

238   interpretation of an IgG positive result is complicated by the possible detection of IgG in acute

239   infections and the potential absence of IgG in some cases of previous infection.

240

241   **Table 2. QUADAS-2 Assessment of Studies**

	Risk of Bias				Applicability Concerns		
Study	Patient Selection	Index Test	Reference Standard	Flow & Timing	Patient Selection	Index Test	Reference Standard
Vickers 2017	Low	Low	Low	Low	High	Unclear	Low
Piedrahita 2016	Low	Low	Low	Low	High	Unclear	Low
Vickers 2015	Low	Low	Low	Low	High	Unclear	Low
Krishnananthasivam 2015	Low	Low	Low	Low	High	Unclear	Low
Lee 2015	Unclear	Low	Low	Low	High	Unclear	Low
Pal 2015	Low	Low	Low	Low	High	Unclear	Low

Sanchez-Vargas 2014	Low	Low	Low	Low	High	Unclear	Low
Pan-Ngum 2013	Low	Low	Low	Low	High	Unclear	Low
Moorthy 2009	Low	Low	Low	Low	High	Unclear	Low
Groen 2000	Low	Low	Unclear	Low	High	Unclear	Unclear

242

243   In the GRADE assessment, the overall certainty of evidence for using dengue RDTs for

244   determination of dengue serostatus was low. The indirectness of evidence was serious given the

245   fact that no study evaluated the RDTs for the detection of remote previous DENV infection only.

246   Additionally, the inconsistency of the studies was serious, as studies varied in how they defined

247   secondary infection, the population studied, the laboratory reference standard used, the cutoffs

248   used to define a positive and negative IgG result, and how samples were chosen for inclusion in

249   the evaluations. Due to these differences across studies, a meta-analysis of data was not

250   conducted. Further data analysis and subpopulation analyses were not done due to the absence

251   of data relating to vaccination status, age groups, other flaviviruses, and time since infection, as

252   well as the overall heterogeneity of study designs.

253

254

255   **Table 3. GRADE Evaluation of Evidence Quality**

Number of Studies	Study Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Quality	Importance

10	Cohort Studies	Not Serious	Serious	Serious	Not Serious	Low	Critical

256

257

258   Semi-structured interviews were conducted with dengue rapid test product managers from 4

259   dengue RDT manufacturers (Abbott/Alere, Bio-Rad, CTK Biotech, and GenBody) who responded

260   to an interview request, along with Sanofi-Pasteur, the manufacturer of Dengvaxia®.

261   Manufacturers noted that dengue RDTs have typically been designed to detect the higher levels

262   of IgG that can be present soon after primary and secondary DENV infections and not low-level

263   IgG, though the specific limit of detection for IgG for each test is not publicly available.

264   Furthermore, current RDTs do not have regulatory approval and were not validated for

265   determination of dengue serostatus. An RDT optimized to detect remote prior infection would

266   benefit from having higher sensitivity for IgG than current RDTs, as IgG levels can wane over the

267   course of time; however, additional testing would be needed to ensure that this does not result

268   in increased cross-reactivity with other flaviviruses. Manufacturers also indicated that this

269   should be technically feasible, given the research already done to develop current RDTs as well

270   as the technical expertise from using and developing laboratory-based ELISA tests, which

271   typically have higher IgG sensitivity. Additional discussions over whether total DENV IgG or IgG

272   specific to particular DENV antigens would be helpful, as well as whether other analytes (e.g.,

273   IgM or other analytes found in current tests) are needed would also be helpful to guide the final

274   design of an RDT.

275

Discussion

In acute secondary DENV infections and convalescent timepoints after recent infection, the

sensitivity and specificity of the IgG component of dengue RDTs was typically above 75% and

80%, respectively, when compared to IgG detection by laboratory-based ELISA testing.

However, a major limitation is the fact that no study evaluated the performance of RDTs for past

DENV infection, as studies only used early convalescent samples or samples from presumed

acute primary or secondary infection. Therefore, no data are available on RDTs that have tested

IgG for DENV infections in the remote past.

Studies varied depending on the population studied, the types of samples included in each

study, how secondary infections were determined, what cutoffs were used to categorized IgG

levels as positive or negative, and the reference standard test used. Sensitivity and specificity of

the IgG component were lower when the dengue samples tested included acute primary

infection samples. This may be due to the lack of IgG or low-levels of IgG present in samples

taken soon after infection, where IgM constitutes the primary initial immune response.

This systematic review did not identify any studies that specifically evaluated dengue RDTs for

determining dengue serostatus in the context of remote prior infection only. The review also

identified four major challenges of use of dengue RDTs for detecting prior infection:

1) **Data challenges**

The studies included in this review evaluated the performance of the IgG component of

dengue RDTs in the following groups: 1) all samples from individuals with suspected

298   DENV infection and/or 2) samples from individuals described as having secondary DENV

299   infection or convalescent timepoints after recent infection. Although these groups are

300   not equivalent to individuals with more remote previous DENV infection, they do provide

301   some insight into the performance of dengue RDTs for identifying IgG antibodies as

302   compared to a laboratory-based test. However, their performance in these populations

303   should be taken as an overestimate compared to an overall population presenting for

304   vaccination screening, since the groups studied typically have higher IgG levels that are

305   much easier to detect compared to a general population. This will primarily impact the

306   sensitivity of the assays. The extent of specificity will vary depending on the population

307   from which dengue-negative reference samples were drawn (e.g., this ranges from using

308   US adults as dengue-negative controls to samples from dengue-endemic populations).

309

310   **2) Regulatory challenges**

311   Determination of dengue serostatus is not explicitly included as an approved part of the

312   intended use statements of dengue RDTs. This is not surprising, given the fact that the

313   primary intention for these RDTs has been the diagnosis of acute DENV infection in

314   patients with febrile illness. However, the label and intended use for some of these

315   tests, where it is described as an aid to "diagnosis of DENV infection" may be interpreted

316   to include determination of past infection. As an example, the SD Bioline Dengue Duo

317   intended use is to "aid in the presumptive diagnosis between primary and secondary

318   dengue infection." However, IgG can still be detected during and shortly after acute

319   primary infection, which can complicate the distinction between primary and secondary

320   infection. Regulatory authorities may interpret use of RDTs for determination of past

321   DENV infection as off-label usage, which may lead to procurement and implementation

322   challenges, depending on local policies. Additional research on the use of RDTs for

323   measuring past infection would benefit from following local and regional regulatory

324   requirements, in order to assist RDTs in obtaining an indication for this use.

325

326   **3) Technical challenges**

327   Since IgG antibody levels can be higher during or soon after acute infection, RDTs that

328   have been optimized to diagnose acute infection may not be suitable for detection of

329   lower IgG antibody levels in individuals with more remote prior DENV infection. This may

330   help to explain the lower sensitivity of the IgG component seen in some studies,

331   although the limit of detection for IgG for each test is not publicly available information.

332   Additionally, dengue serological tests can cross-react with antibodies to other

333   flaviviruses, such as West Nile virus and Zika virus, and none of the studies in this review

334   characterized the occurrence of other flaviviruses in their sample sets. Lowering the titer

335   of IgG antibodies that RDTs can detect in order to increase sensitivity for detection of

336   past infection may also lead to lower specificity. More specific antigens could also be

337   explored. Furthermore, specificity may vary depending on the prevalence of other

338   flavivirus infections as well as vaccinations used for other flaviviruses. Therefore, the

339   relatively high sensitivity and specificity of RDTs may show that they match up well with

340   commercial ELISAs designed to diagnose acute infection only. Additional research would

341   be helpful to compare RDTs not only to ELISAs, but also to PRNT assays, which may be a

342   more specific measure of DENV exposure and may be a superior reference standard.

343

344   **4) Impact of Zika virus**

345   Most of the evaluations were conducted before the emergence of Zika virus, which is

346   highly related to DENV. However, recent research on antibody cross-neutralization

347   suggests that ZIKV lies outside the dengue virus serocomplex [35]. In a study on

348   longitudinal serologic specimens from Latin America and Asia, ZIKV neutralizing antibody

349   titers in patients after ZIKV showed low-level cross-reactivity to DENV that was greater in

350   dengue-immune individuals [35]. These antibodies may be able to distinguish ZIKV from

351   DENV infections, although additional research is needed to determine this. Over time it

352   may become harder to distinguish the two viruses, and more specific antigens or tests

353   may be necessary.

354

355 Strengths of this systematic review included over 3000 DENV samples tested, including a

356 smaller subset of secondary infections and convalescent timepoints after recent infection, the

357 geographic diversity of studies, and the inclusion of a number of different commercially-

358 available dengue RDTs and sample types. However, the review was limited by the heterogeneity

359 of data and the inability to evaluate factors such as infection with other flaviviruses and the

360 potential impact of other flavivirus vaccines.

361

362 With such a paucity of data on the use of dengue RDTs for determining serostatus, further

363 research is necessary to inform pre-vaccination screening approaches for dengue, as it is

364 currently difficult to draw distinct conclusions regarding the performance of RDTs for this use.

365 Studies could examine the performance of current RDTs for the direct purpose of determining

366 serostatus, investigate the performance of the test in areas with co-circulating flaviviruses and

367 vaccination, and assess the use of other reference standards such as PRNT. Based on the

368 performance of currently available dengue RDTs in secondary infection and convalescent

369 timepoints after recent infection, the IgG component of these RDTs do have reasonable

370 performance for detection of these infections compared to conventional laboratory-based ELISA

371 testing. However, further discussion within the scientific and public health community is

372 needed to determine if this performance is sufficient for pre-vaccination screening or not. The

373 decision to use RDTs will likely also depend on local factors, such as dengue seroprevalence, the

374 availability of alternative tests, and the public health risk and benefit from vaccination.

375

376 Development of new dengue RDTs or modification of currently available RDTs may be the most

377 beneficial for vaccination screening. Tests with higher sensitivity and specificity, and even new

378 antigen or antibody targets can be investigated and validated by dengue RDT manufacturers,

379 who have the necessary expertise to provide regulatory approved tests suitable for pre-

380 vaccination screening [35]. Alternatively, in settings with sufficient laboratory capacity,

381 laboratory-based testing may also considered, although slower turnaround time of these tests

382 may lead to high rates of individuals not returning for their test results or vaccination [36].

383 Vaccination programs should evaluate all currently available testing options to determine how

384   best to evaluate for dengue serostatus in order to ensure safe and effective vaccination. New

385   tests may be needed with high sensitivity and specificity at the point-of-care to avoid excluding

386   individuals who would benefit from vaccination while at the same time preventing the inclusion

387   of individuals who should not be vaccinated.

Acknowledgments

Transparency Declaration

References

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504-507.

2. Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358(6365):929-932.

3. Wilder-Smith A, Gubler DJ, Weaver SC, Monath TP, Heymann DL, Scott TW. Epidemic arboviral diseases: priorities for research and public health. Lancet Infect Dis. 2017;17(3):e101-e106.

4. Jentes ES, Lash RR, Johansson MA, Sharp TM, Henry R, Brady OJ, et al. Evidence-based risk assessment and communication: a new global dengue-risk map for travellers and clinicians. J Travel Med. 2016;23(6).

5. Olivero RM, Hamer DH, MacLeod WB, Benoit CM, Sanchez-Vargas C, Jentes ES, et al. Dengue virus seroconversion in travelers to dengue-endemic areas. Am J Trop Med Hyg. 2016.

6. Neuberger A, Turgeman A, Lustig Y, Schwartz E. Dengue fever among Israeli expatriates in Delhi, 2015: implications for dengue incidence in Delhi, India. J Travel Med. 2016;23(3).

7. Riddell A, Babiker ZO. Imported dengue fever in East London: a 6-year retrospective observational study. J Travel Med. 2017;24(3).

8. Ferguson RW, Henderson SJ, Lee EA, Jung P. Dengue in Peace Corps volunteers, 2000-14. J Travel Med. 2016;23(3).

9. Kittayapong P, Olanratmanee P, Maskhao P, Byass P, Logan J, Tozan Y, et al. Mitigating diseases transmitted by Aedes mosquitoes: A cluster-randomised trial of permethrin-impregnated school uniforms. PLoS Negl Trop Dis. 2017;11(1):e0005197.

418   10. Andersson N, Nava-Aguilera E, Arosteguí J, Morales-Perez A, Suazo-Laguna H, Legorreta-

419   Soberanis J, et al. Evidence based community mobilization for dengue prevention in Nicaragua

420   and Mexico (Camino Verde, the Green Way): cluster randomized controlled trial. BMJ. 2015 Jul

421   8;351:h3267.

422   11. Lalani T, Yun H, Tribble D, Ganesan A, Kunz A, Fairchok M, et al. A comparison of compliance

423   rates with anti-vectorial protective measures during travel to regions with dengue or

424   chikungunya activity, and regions endemic for Plasmodium falciparum malaria. J Travel Med.

425   2016;23(5).

426   12. SAGE Working Group on Dengue Vaccines, WHO Secretariat. Background paper on dengue

427   vaccines. 2016.

428   13. Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, et al. Effect of dengue

429   serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018.

430   14. Wilder-Smith A. Serostatus-dependent performance of the first licensed dengue vaccine:

431   implications for travellers. J Travel Med. 2018 Aug 1;25(1).

432   15. WHO. Updated questions and answers related to the dengue vaccine Dengvaxia® and its

433   use. 22 December 2017.

434   http://www.who.int/immunization/diseases/dengue/q_and_a_dengue_vaccine_dengvaxia_use

435   16. WHO. Revised SAGE recommendation on use of dengue vaccine. 19 April 2018.

436   http://www.who.int/immunization/diseases/dengue/revised_SAGE_recommendations_dengue

437   _vaccines_apr2018/

438 17. Wilder-Smith A, Hombach J, Ferguson N, Selgelid M, O'Brien K, Vannice K, et al.

439 Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV

440 dengue vaccine. Lancet Infect Dis. 2018 Sep 5. pii: S1473-3099(18)30494-8.

441 18. Goncalves A, Peeling RW, Chu MC, Gubler DJ, de Silva AM, Harris E, et al. Innovative and new

442 approaches to laboratory diagnosis of Zika and Dengue: A meeting report. J Infect Dis.

443 2018;217(7):1060-1068.

444 19. WHO. Dengue guidelines for diagnosis, treatment, prevention and control. 2009.

445 20. CDC. Laboratory Guidance and Diagnostic Testing: Dengue. 3 August 2017.

446 21. Arien KK, Wilder-Smith A. Dengue vaccine: reliably determining previous exposure. The

447 Lancet Global health. 2018

448 22. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting Items for

449 systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.

450 23. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a

451 revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med.

452 2011;155:529–536.

453 24. Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality

454 of evidence and strength of recommendations for diagnostic tests and strategies. BMJ.

455 2008;336:1106–1110.

456 25. Vickers I, Harvey K, Nelson K, Brown M, Bullock-DuCasse M, Lindo J. Evaluation of OneStep

457 Dengue NS1 RapiDip™ InstaTest and OneStep Dengue Fever IgG/IgM RapiCard™ InstaTest during

458 the course of a dengue type 1 epidemic. Diagn Microbiol Infect Dis. 2017 Dec;89(4):271-275.

459 26. Piedrahita LD, Agudelo IY, Trujillo AI, Ramírez RE, Osorio JE, Restrepo BN. Evaluation of

460 commercially available assays for diagnosis of acute dengue in schoolchildren during an

461 epidemic period in Medellin, Colombia. Am J Trop Med Hyg. 2016 Aug 3;95(2):315-21.

462 27. Vickers IE, Harvey KM, Brown MG, Nelson K, DuCasse MB, Lindo JF. The performance of the

463 SD BIOLINE Dengue DUO® rapid immunochromatographic test kit for the detection of NS1

464 antigen, IgM and IgG antibodies during a dengue type 1 epidemic in Jamaica. J Biomed Sci. 2015

465 Jul 16;22:55.

466 28. Krishnananthasivam S, Fernando AN, Tippalagama R, Tennekoon R, De Man J, Seneviratne D,

467 et al. Evaluation of a commercial rapid test kit for detection of acute dengue infection.

468 Southeast Asian J Trop Med Public Health. 2015 Jul;46(4):602-10.

469 29. Lee J, Kim YE, Kim HY, Sinniah M, Chong CK, Song HO. Enhanced performance of an

470 innovative dengue IgG/IgM rapid diagnostic test using an anti-dengue EDI monoclonal antibody

471 and dengue virus antigen. Sci Rep. 2015 Dec 11;5:18077.

472 30. Pal S, Dauner AL, Valks A, Forshey BM, Long KC, Thaisomboonsuk B, et al. Multicountry

473 prospective clinical evaluation of two enzyme-linked immunosorbent assays and two rapid

474 diagnostic tests for diagnosing dengue fever. J Clin Microbiol. 2015 Apr;53(4):1092-102.

475 31. Sánchez-Vargas LA, Sánchez-Marce EE, Vivanco-Cid H. Evaluation of the SD BIOLINE Dengue

476 Duo rapid test in the course of acute and convalescent dengue infections in a Mexican endemic

477 region. Diagn Microbiol Infect Dis. 2014 Apr;78(4):368-72.

478 32. Pan-ngum W, Blacksell SD, Lubell Y, Pukrittayakamee S, Bailey MS, Janaka de Silva H, et al.

479 Estimating the true accuracy of diagnostic tests for dengue infection using bayesian latent class

480 models. PLoS One. 2013;8(1):e50765.

481   33. Moorthy M, Chandy S, Selvaraj K, Abraham AM. Evaluation of a rapid

482   immunochromatographic device for the detection of IgM & IgG antibodies to dengue

483   viruses (DENV) in a tertiary care hospital in south India. Indian J Med Microbiol. 2009 Jul-

484   Sep;27(3):254-6.

485   34. Groen J, Koraka P, Velzing J, Copra C, Osterhaus AD. Evaluation of six immunoassays for

486   detection of dengue virus-specific immunoglobulin M and G antibodies. Clin Diagn Lab Immunol.

487   2000 Nov;7(6):867-71.

488   35. Montoya M, Collins M, Dejnirattisai W, Katzelnick LC, Puerta-Guardo H, Jadi R, et al.

489   Longitudinal analysis of antibody cross-neutralization following Zika virus and dengue virus

490   infection in Asia and the Americas. J Infect Dis. 2018 Jul 13;218(4):536-545.

491   36. Nascimento EJM, George JK, Velasco M, Bonaparte MI, Zheng L, DiazGranados CA, et al.

492   Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus. J Virol

493   Methods. 2018 Jul;257:48-57.